http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018188474-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
filingDate | 2018-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64273a90f1093784c5e167be40808a9e |
publicationDate | 2018-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2018188474-A |
titleOfInvention | Deuterated CFTR enhancer |
abstract | A novel ivacaftor derivative for treating diseases and conditions that are advantageously treated by administering a CFTR (cystic fibrosis transmembrane conductance regulator) enhancer, and pharmaceutically acceptable derivatives thereof A composition comprising the salt. A compound of formula I: And pharmaceutically acceptable salts thereof. In which Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , and Y 6 are each independently CH 3 or CD 3 , and Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , and Y When all 6 are CH 3 , at least one of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 is deuterium. [Selection figure] None |
priorityDate | 2018-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 468.